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OBJECTIVE — Multifaceted care has been shown to reduce mortality and complications in
type 2 diabetes. We hypothesized that structured care would reduce renal complications in type
2 diabetes.
RESEARCH DESIGN AND METHODS — A total of 205 Chinese type 2 diabetic pa-
tients from nine public hospitals who had plasma creatinine levels of 150–350 mol/l were
randomly assigned to receive structured care (n  104) or usual care (n  101) for 2 years. The
structured care group was managed according to a prespeciﬁed protocol with the following
treatment goals: blood pressure 130/80 mmHg, A1C 7%, LDL cholesterol 2.6 mmol/l,
triglyceride 2 mmol/l, and persistent treatment with renin-angiotensin blockers. The primary
end point was death and/or renal end point (creatinine 500 mol/l or dialysis).
RESULTS — Ofthese205patients(meanSDage657.2years;diseaseduration147.9
years), the structured care group achieved better control than the usual care group (diastolic
blood pressure 68  12 vs. 71  12 mmHg, respectively, P  0.02; A1C 7.3  1.3 vs. 8.0 
1.6%, P  0.01). After adjustment for age, sex, and study sites, the structured care (23.1%, n 
24) and usual care (23.8%, n  24; NS) groups had similar end points, but more patients in the
structured care group attained 3 treatment goals (61%, n  63, vs. 28%, n  28; P  0.001).
Patients who attained 3 treatment targets (n  91) had reduced risk of the primary end point
(14 vs. 34; relative risk 0.43 [95% CI 0.21–0.86] compared with that of those who attained 2
targets (n  114).
CONCLUSIONS — Attainment of multiple treatment targets reduced the renal end point
anddeathintype2diabetes.Inadditiontoprotocol,auditsandfeedbackareneededtoimprove
outcomes.
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A
though the Steno-2 study reported
thatmultifacetedcarebyamultidis-
ciplinary team reduced all-cause
mortality and cardiovascular complica-
tionsintype2diabetes(1,2),theseresults
needtobeconﬁrmedinamulticenterset-
ting. In addition, renal insufﬁciency is a
powerfulpredictorforcardiovasculardis-
eases (3), and type 2 diabetes is the main
cause of end-stage renal disease (ESRD)
(4). The effects of multifaceted care on
ESRD remain unexplored. We have re-
ported 50–70% risk reduction in death
and cardiorenal complications in type 2
diabetic patients managed by a diabetolo-
gist-led team (5,6) compared with usual
care. In this randomized multicenter
study, we compared the effects of struc-
tured care with predeﬁned protocol and
treatment targets, delivered by a diabe-
tologist-led team, on death and ESRD
compared with usual care.
RESEARCH DESIGN AND
METHODS— In this 2-year random-
ized, multicenter study, which com-
menced in 2003 and completed in 2007,
205 type 2 diabetic patients with renal
insufﬁciency were recruited from nine
public hospitals. Each hospital runs a
weekly session in which 10–15 diabetic
patients undergo comprehensive assess-
ment (7) and from which patients with
plasma creatinine levels 150 mol/l
were invited for recruitment. All patients
had ultrasound scanning to exclude re-
versible causes of renal insufﬁciency, e.g.,
renal artery stenosis.
With written informed consent, eligi-
ble patients were randomly assigned in a
1:1 manner to receive either structured
care or usual care using a computer-
generated allocation code with equal
numbers in each group within the same
hospital.Thesealedenvelopewasopened
sequentially by nonstudy personnel. The
structured care group was followed up at
the Diabetes Centre by the specialist team
using a predeﬁned protocol, whereas the
usual care group was managed in their
original clinic but returned for assess-
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by the research ethics committee of each
institution.
Inclusion criteria included a diagnosis
of type 2 diabetes (8), age 35–75 years (in-
clusive), and plasma creatinine level 150–
350 mol/l (inclusive). Exclusion criteria
included malignancy or life-threatening
diseases; nondiabetes renal disease (e.g.,
biopsy-proven glomerulonephritis or
obstructive uropathy); unstable psychiat-
ric illnesses, and renal function (20%
difference in two consecutive plasma cre-
atinine values within 3 months before
recruitment).
Theprimarycompositeendpointwas
death and/or ESRD, deﬁned as the need
for dialysis, or plasma creatinine level
500 mol/l. The secondary end point
was the percentage of patients attaining
3treatmenttargetsandtheirimpactson
clinical outcomes.
Structured care
The structured care group was managed
by a diabetes team including diabetolo-
gists, endocrine trainees, and diabetes
nurses using a preprinted case report
book containing predeﬁned scheduled
visits, assessment items, and treatment
targets deﬁned as follows: 1) blood pres-
sure 130/80 mmHg, 2) A1C 7%, 3)
calculated LDL cholesterol 2.6 mmol/l,
4) fasting plasma triglyceride 2 mmol/l,
and 5) treatment with ACE inhibitors
and/or angiotensin receptor blockers
(ARBs) unless patients developed persis-
tent hyperkalemia (5.5 mmol/l) or an
acuteriseinplasmacreatinine(e.g.,30%)
upon drug introduction or dose titration.
The structured care group was seen
by a dietitian upon randomization to re-
inforce a low-protein and low-potassium
diet. ACE inhibitor or ARB therapy was
started in treatment-naive patients with
monitoringofrenalfunctionatweek2,then
every 4 weeks for 12 weeks and subse-
quently every 8–12 weeks, throughout the
study period. All patients were seen by a
doctor-nurse team every 3 months and
more often if indicated. At each visit, blood
pressure,bodyweight,andlaboratorymea-
surementswereperformedaccordingtothe
protocol. Treatment compliance and self-
care including drug use, insulin injection,
self-monitoring of blood glucose, and life-
style modiﬁcation were reinforced by
nurses either during clinic visits or using
telephone calls. Patients also returned be-
tweenclinicvisitsformeasurementofblood
pressureandbodyweightandbloodtaking
by nurses (to test plasma glucose, A1C, and
renal function). All laboratory results were
availableforreviewbyadoctoratthesched-
uled visit for decision making. Complete
bloodresults,plasmalipidlevels(totalcho-
lesterol, HDL cholesterol, triglyceride, and
calculated LDL cholesterol), and a bone
proﬁleweremeasuredevery6months.Fig-
ure 1 shows the overall study design and
clinical outcomes for recruited patients.
Usual care
To ensure applicability of the results, pa-
tientsrandomlyassignedtotheusualcare
group were managed according to the
usual clinic practice as deﬁned by the re-
spective hospital with no modiﬁcation.
Thus, patients might attend a diabetes
clinic (managed by a diabetes team) or a
general medical clinic (managed by a
nondiabetes specialist or an internist),
usuallyat3-to4-monthintervals.Allhad
access to laboratory tests, investigations,
and counseling from a pharmacist, edu-
cator, or dietitian, but these were ordered
at the doctor’s discretion. Because differ-
ent hospitals adopted different systems to
manage diabetic patients, in some study
sites, diabetic patients randomly assigned
tousualcarewerefollowedupregularlyat
diabetesspecialistclinicswithacarestan-
dard comparable to that of the structured
care group.
Statistical analysis
In a pilot study, the 2-year incidence of
ESRD was 30% in 80 type 2 diabetic pa-
tients with plasma creatinine levels of
150–350mol/lwhoreceivedstructured
care by a specialist team compared with
50% in a matched cohort receiving usual
care in the same hospital. By using 
0.8 and 0.05, the sample size was 96
for each group with a recruitment target
Figure 1—Overall study design and clinical outcomes of recruited patients.
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20% default rate.
All data were analyzed by SPSS (Win-
dowsversion15.0;SPSS,Chicago,IL)us-
ingintention-to-treatanalysisfollowedby
per-protocol analysis, as deﬁned by at-
tainment of 3 treatment goals. All re-
sults are expressed as mean  SD, n
(percent), or median (range) where ap-
propriate. Student’s t test, 
2 test, and
ANCOVA after adjustment for age, sex,
and study centers were used for between-
group comparisons. Relative risk (RR) re-
duction (95% CIs) was reported using
Kaplan-Meier analysis. P  0.05 (two-
sided) was signiﬁcant.
RESULTS— Of 205 patients recruited
(mean  SD age of 65  7.2 years and
disease duration of 14  7.9 years), 104
were randomly assigned to structured
care and 101 to usual care. The groups
had similar clinical proﬁles except that
the structured care group had a higher
frequency of sensory neuropathy, coro-
nary heart disease (CHD), and usage of
ACE inhibitors or ARBs than the usual
care group. Of these patients, 167 com-
pleted the 2-year study (84 structured
care and 83 usual care). Reasons for with-
drawal included death (n  19), consent
withdrawal (n  3), loss to follow-up
(n  2), and referral to a nephrologist for
dialysis (n  14) (Table 1; Fig. 1).
In both groups, the composite end
point occurred in 24 patients (RR 0.96
[95%CI0.50–1.84])withsimilarratesof
clinicalevents,hospitalization,andemer-
gency room visits (Table 1). Among the
ninestudysites,thestructuredcaregroup
had fewer event rates than the usual care
group in ﬁve hospitals, higher rates in two
hospitals,andsimilarratesintwohospitals.
At 2 years and after adjustment for
age, sex, and study sites, the structured
caregrouphadlowerdiastolicbloodpres-
sure and A1C levels and were more likely
to attain 3 treatment goals (61% [n 
63]vs.28%[n28])(Table2).Withper
protocol analysis, patients who attained
3 treatment goals (n  91) had a 60%
risk reduction in reaching the primary
end point compared with those who did
not attain 3 treatment goals (n  114)
(14 vs. 34; RR 0.43 [95% CI 0.21–0.86])
(Table 3; Fig. 2).
CONCLUSIONS — In this multi-
center, randomized translational study,
we tested the superiority of protocol-
driven care delivered by a diabetologist-
nurse team over usual care in reducing
deathandESRD.Weobservedthatattain-
ment of 3 treatment goals (blood pres-
sure, A1C, LDL cholesterol, triglycerides,
and use of ACE inhibitors or ARBs) rather
than structured care was associated with
improved clinical outcomes.
To date, most clinical studies are
“mechanism research,” with the aim of
understanding disease causality and efﬁ-
cacyofinterventionsundercontrolleden-
vironments. This type of research does
not address issues such as barriers in
Table 1—Baseline clinical and biochemical characteristics and end of study clinical events in
205 type 2 diabetic patients with renal insufﬁciency randomly assigned to receive either
structured or usual care for 2 years
Structured care Usual care
At baseline
n 104 101
Age (years) 64.6  7.5 65.4  6.9
Male sex (%) 66 67
Duration of diabetes (years) 14.4  7.9 13.8  7.9
BMI (kg/m
2) 25.4  3.5 25.4  3.8
Systolic blood pressure (mmHg) 145  23.7 144  26.7
Diastolic blood pressure (mmHg) 74  11.7 74  10
Waist circumference (cm) 90.1  9.2 89.3  9.0
Waist-to-hip ratio 0.95  0.06 0.94  0.06
Coexisting diseases (%)
Hypertension 96 96
Coronary heart disease* 19 12
Congestive heart failure 8 7
Myocardial infarction 1 3
Revascularization 2 3
Peripheral vascular disease 1 1
History of cerebrovascular accident 14 16
Retinopathy 50 38
Sensory neuropathy 20 34
Medications (%)
ACE inhibitor or ARB 77 56
Aspirin 37 30
Statin 48 42
Fibrate 9 8
Insulin 61 58
No. of blood pressure–lowering drugs 2.9  1.2 2.4  1.1
At 2 years
No. of patients with composite renal end point 24 24
ESRD (Cr 500 mol/l) 16 15
Dialysis 10 8
Death 8 11
No. of patients with composite cardiovascular
end point 21 19
Hospitalization for heart failure 13 15
Hospitalization for angina 1 0
Hospitalization for arrhythmia 5 1
Myocardial infarction 4 4
Revascularization (PTCA/CABG) 1 1
Other revascularization 1 0
CVA or transient ischemic attack 2 3
Lower-limb amputation 1 0
Emergency room visits (n) 1 (0–8) 1 (0–18)
Hospitalizations (n) 1 (0–15) 1 (0–13)
Days of hospitalization 2 (0–93) 2 (0–116)
Data are means  SD, n, %, or median (range). P values comparing SC and UC: all NS. *Coronary heart
disease includes symptoms of angina or an abnormal electrocardiogram with conﬁrmed stress test and/or
coronary angiogram. CABG, coronary artery bypass graft; Cr, serum creatinine; CVA, cerebrovascular acci-
dent; PTCA, percutaneous transluminal coronary angioplasty.
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practice. “Translational research” is more
focused on outcomes of practical rele-
vance to patients, health care providers,
and health care systems. It examines the
relationships between structural factors
(e.g., practice structure and health care
personnel), care processes (e.g., frequen-
cies of measurements of A1C), and health
outcomes in the real-life setting. Thus,
whereas translational research has higher
external validity (i.e., the possibility of
generalizing study results), it has lower
internal validity (i.e., the strength of the
causal relationship between intervention
andoutcomeofinterest)thanmechanism
research. Nevertheless, these two types of
research are complementary because
once the evidence base of an intervention
isestablished,thereisaneedtotranslateit
to practice. With the growing popularity
of chronic disease management, transla-
tion research is important in evaluating
the effectiveness of these programs.
Several factors may explain our fail-
ure to prove that structured care was bet-
ter than usual care in improving clinical
outcomes. These include underpower of
the study because of general improve-
ment in the care standard, contamination
by specialist care in the usual care group,
and insufﬁcient auditing to ensure ad-
herence to the structured care protocol.
Whenweﬁrstconceptualizedthestudyin
2000, we used data available then to esti-
mate sample size. In the Asian subgroup
analysis of the Reduction of End Points in
Type 2 Diabetes With the Angiotensin II
Antagonist Losartan (RENAAL) study,
which examined the renoprotective ef-
fectsoflosartanintype2diabeticpatients
withplasmacreatinine(110–260mol/l)
levels lower than those of the present co-
hort(150–350mol/l),the3-yearcumu-
lative incidence of the primary end point
ofdeathandESRDwas48%(9).Inasub-
sequentproof-of-conceptstudyinvolving
patients with renal function comparable
to that of the present cohort, the 2-year
cumulative incidence of death and ESRD
was50%intheusualcaregroupand25%
in the structured care group (6). Com-
pared with these two studies (1997–
2002),the2-yearcumulativeincidenceof
the primary end point in the present co-
hort (2003–2007) was 24% in both the
structured care and usual care groups.
These ﬁndings suggest that increasing
awareness of the beneﬁcial effects of in-
tensive risk factor control and inhibition
of the renin-angiotensin system (10)
might have led to improvement in the
carestandardandthereducedrateofclin-
ical end points, at least in the Hong Kong
setting.
Although this improvement in the
care standard might have attenuated the
beneﬁts of structured care in our study,
consistent with our predeﬁned hypothe-
sis, more patients in the structured care
group attained 3 treatment goals (61%)
than in the usual care group (28%). This
Table 2—Metabolic control and attainment of treatment goals in type 2 diabetic patients with
renal insufﬁciency randomly assigned to either usual or structured care for 2 years
Structured care Usual care P*
Completed 2 years of follow-up
(%)
81 82 0.55
Systolic blood pressure (mmHg)
Baseline 145  24 144  26 0.15
Last available 135  25 137  21 0.15
Diastolic blood pressure (mmHg)
Baseline 74  12 74  10 0.93
Last available 68  12 71  12 0.02
A1C (%)
Baseline 8.2  1.9 8.4  0.2 0.62
Last available 7.3  1.3 8.0  1.6 0.01
Plasma triglycerides (mmol/l)
Baseline 2.3  1.7 2.5  2.2 0.61
Last available 1.8  1.3 1.9  1.1 0.06
HDL cholesterol (mmol/l)
Baseline 1.2  0.3 1.2  0.3 0.84
Last available 1.2  0.4 1.2  0.3 0.45
LDL cholesterol (mmol/l)
Baseline 3.1  1.1 3.0  1.0 0.60
Last available 2.49  0.81 2.84  1.1 0.14
Serum creatinine (mol/l)
Baseline 196.3  3.5 198.8  48.7 0.68
Last available 281.9  134.7 290.3  28.7 0.37
Estimated glomerular ﬁltration rate
(ml/min per 1.73m
2)
Baseline 31.4  8.14 31.3  8.2 0.96
Last available 24.0  10.2 26.6  12.4 0.11
Use of ACE inhibitors or ARBs (%)
Baseline 77 56 0.01
Last visit 69 49 0.01
Use of insulin (%)
Baseline 61 58 0.75
Last visit 65 71 0.29
Patients attaining number of
targets at last review visit (%)
02 9
11 3 1 9
22 4 4 5
32 9 1 6
42 2 9
51 0 3
Attained at least 3 treatment goals
(%)
61 28 0.01
% of patients attaining treatment
target at last review visit
Blood pressure 130/80 mmHg 49 27 0.01
LDL cholesterol 2.6 mmol/l 56 41 0.02
Triglycerides 2.0 mmol/l 63 47 0.24
A1C 7% 39 26 0.19
Data are means  SD or %. *After adjustment for age, sex, and study centers.
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reduction in premature death and ESRD.
In an observational study of 6,386 type 2
diabetic patients, attainment of 2 treat-
ment goals (A1C, blood pressure, or LDL
cholesterol) was associated with 30–50%
risk reduction in new onset of CHD (11).
These ﬁndings strongly support the need
to attain multiple treatment targets to im-
provecardiorenalcomplicationsintype2
diabetes.Becauseofthesmallsamplesize,
we were unable to stratify patients by se-
verity of renal function to perform sub-
group analysis.
Although the structured care group
was three times (61%) more likely than
the usual care group (28%) to attain 3
treatment targets, there was considerable
heterogeneityineventratesamonghospi-
tals, possibly due to different care sys-
tems. In two study sites, event rates were
higher in the structured care group; in
one, the result was due to a higher base-
line plasma creatinine level in the struc-
tured care group, and in another, the
usualcaregroupwasmanagedbythespe-
cialist team with regular review meetings.
These ﬁndings have provided important
insights into the potential effects of care
organization on clinical outcomes. Thus,
to fully realize the beneﬁts of protocol-
drivencare,trainedpersonnelorinforma-
tion technology is needed to ensure
adherence to protocol and attainment of
treatment targets through regular audits
and feedback, a setup not dissimilar to a
clinical trial setting (12). However, be-
cause of resource limitation, we were un-
able to implement these measures to
complete the cycle of quality planning,
assurance, and improvements (13).
There are also multiple barriers to
translating evidence to practice at the lev-
els of patients, care providers, and health
care systems (14,15). In most clinical au-
dits, 10% of type 2 diabetic patients at-
tained 3 treatment goals of blood
pressure, LDL cholesterol, and A1C (15).
In addition, 20–50% of patients were
noncompliantwithlife-savingdrugssuch
asstatins(16,17).Whereasclinicalinertia
of physicians might delay commence-
ment or escalation of therapy (18), fre-
quent testing of risk factors may not
translate to changes in treatment regi-
mens (19). Although use of e-mails and
telephone calls improved doctors’ adher-
ence to some performance indexes (e.g.,
bloodtests),theeffectsofthesebehavioral
changes on clinical outcomes have not
been explored (20). Conversely, in a
2-year randomized study, regular tele-
phone calls by a pharmacist to reinforce
compliance and ensure continuation of
care reduced mortality and hospitaliza-
tion by 30–50% in patients receiving 5
chronic medications including drugs for
diabetes and CHD (17).
Figure2—Kaplan-Meieranalysisshowingthecumulativeincidenceoftheprimarycompositeend
pointofdeathorESRDdeﬁnedasdialysisortheneedfordialysisorplasmacreatininelevel500
mol/l in type 2 diabetic patients with renal insufﬁciency stratiﬁed by attainment of3 prespeci-
ﬁed treatment targets. Treatment targets: 1) blood pressure 130/80 mmHg, 2) A1C 7%, 3)
LDL cholesterol 2.6 mmol/l, 4) fasting plasma triglyceride 2 mmol/l, and 5) treatment with
ACE inhibitors and/or ARBs.
Table3—Majorclinicaleventsintype2diabeticpatientswithrenalinsufﬁciencystratiﬁedby
attainment of >3 prespeciﬁed treatment targets after 2 years of follow-up
Attained 3
treatment
goals*
Attained 2
treatment
goals* P†
n 91 114
Composite primary end point 14 34 0.04
Dialysis 6 12 0.28
ESRD (Cr 500 mol/l) 10 21 0.14
Death 4 15 0.11
Composite cardiovascular end point 19 21 0.22
Hospitalization for heart failure 12 16 0.77
Hospitalization for arrhythmia 4 2 0.41
Acute myocardial infarction 3 5 0.97
Revascularization (PTCA/CABG) 1 1 0.83
Hospitalization for angina 0 1 0.31
Other revascularization 0 1 0.99
Lower-limb amputation 1 0 0.14
Data are n. *Treatment targets: 1) blood pressure 130/80 mmHg, 2) A1C 7%, 3) LDL cholesterol 2.6
mmol/l,4)fastingplasmatriglyceride2mmol/l,and5)treatmentwithACEinhibitorsand/orARBs.†After
adjustment for age, sex, and study centers. CABG, coronary artery bypass graft; Cr, serum creatinine; PTCA,
percutaneous transluminal coronary angioplasty.
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diseases such as diabetes, an integrated
approach including early diagnosis, risk
stratiﬁcation, use of protocols with pre-
deﬁned follow-up schedules, assess-
ments, prompts for intervention further
augmented by audits, and patient em-
powerment is needed to achieve desired
outcomes (13). It has been suggested that
if the specialist-led team care in the
Steno-2studycanbetranslatedtothepri-
mary care setting, such a model can be
cost-saving (21). However, the challenge
lies in identifying effective measures to
ensure integration between different care
providers with adequate communication
and quality assurance. To this end,
change in the practice environment to
promote multidisciplinary care and self-
management (22), a community-based
shared care program (23), and pay-for-
performance schemes (24) have im-
provedadherencetotreatmentguidelines
and metabolic control in type 2 diabetes.
In summary, type 2 diabetic pa-
tients with renal insufﬁciency receiving
protocol-driven care delivered by a di-
abetes specialist team were more likely
to attain multiple treatment targets,
which was associated with a reduced
risk of death and/or ESRD, than those
receiving usual care. Clinical audits and
regularfeedbacktodoctorsandpatients
may further improve compliance to
structured care protocols and reduce
the rate of clinical events.
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